LOS ANGELES--(BUSINESS WIRE)--Today, Mandos, LLC (Mandos) announced they have entered into an agreement with Vtesse, LLC, a wholly owned subsidiary of Mallinckrodt Pharmaceuticals (Mallinckrodt), a global biopharmaceutical company, to acquire adrabetadex (also known as VTS-270), a drug in development for the treatment of Niemann-Pick Type C1 disease (NPC1).
This acquisition, if approved, will allow Mandos to pursue both the continuation of the U.S. Expanded Access Program under Rush University Medical Center (RUMC) and future research and development of adrabetadex for patients living with NPC1. The agreement is subject to approval from the United States Bankruptcy Court for the District of Delaware, as a result of Mallinckrodt’s ongoing Chapter 11 restructuring.
Niemann-Pick Type C1 disease (NPC1) is a rare progressive genetic disorder characterized by an inability of the body to transport cholesterol and other fatty substances (lipids) inside of cells. This leads to the abnormal accumulation of these substances within various tissues of the body, including brain, liver, spleen and lung tissue. As the disease progresses, patients typically exhibit a decline in neurological and cognitive function, often with independent changes in muscle tone and strength.
“We look forward to engaging with this passionate community of patients, caregivers, clinicians, and regulators over the coming months, once the transaction is approved. We care deeply about ensuring access for patients and are committed to supporting efforts to improve the lives of people with NPC1,” said Scott Riccio, EVP, Patient & Community Engagement at Mandos.